Bone densitometry vendorHologic last week announced strong revenue and income growth forthe third quarter (end-June). The company's prospects have beenhelped by the Health Care Financing Administration's decisionto provide Medicare reimbursement for dual
Bone densitometry vendorHologic last week announced strong revenue and income growth forthe third quarter (end-June). The company's prospects have beenhelped by the Health Care Financing Administration's decisionto provide Medicare reimbursement for dual energy x-ray examinations(DXA) to measure bone density.
Hologic, of Waltham, MA, recorded third-quarter revenues of$10.9 million, up 65% from $6.6 million in the same quarter ayear ago. Hologic enjoyed net income of $1.2 million, comparedto a net loss of $169,000 in the third quarter of last year.
Hologic's sales were led by its QDR bone densitometers, inparticular QDR-2000plus, according to chairman and CEO David Ellenbogen.The system was introduced in September 1993.
In addition to Medicare reimbursement, Hologic has been helpedby a Japanese initiative to provide widespread osteoporosis screeningfor its citizens. Hologic has also seen sales grow in PacificRim and Latin American countries, the company said.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.